This study involves adults with end-stage kidney disease (ESKD) who are on dialysis. It aims to evaluate a drug called **Clazakizumab (CSL300)**, focusing on its effects on cardiovascular (CV) health and safety. The study has two parts: the first part finds the right dose, and the second part checks how well the drug works and its safety. Participants must be at least 18 years old, have been on dialysis for at least 12 weeks, and have a high level of inflammation in their blood. They should also have either diabetes or atherosclerotic cardiovascular disease (ASCVD). People who have already participated in the first part of the study or have certain other health conditions cannot join. The study is double-blind, meaning neither the participants nor the researchers know who is receiving the actual drug or a placebo (a substance with no active drug). This ensures unbiased results.

• **Duration:** Participation requires long-term involvement across multiple visits.
• **Eligibility:** Only those with specific medical conditions can participate.
• **Safety:** Participants will be monitored for drug effects and side effects.